Lenalidomide use in multiple myeloma

Lenalidomide use in multiple myeloma (Review) - PMC

Lenalidomide can directly induce MM cell apoptosis and cell cycle arrest. Previous studies have demonstrated several downstream changes after lenalidomide ...

Revlimid (Lenalidomide) - International Myeloma Foundation

REVLIMID® (lenalidomide) is an immunomodulatory drug (IMiD®). It was first approved by the U.S. Food and Drug Administration (FDA) in 2006 for use with the ...

How to Manage Patients with Lenalidomide-Refractory Multiple ...

Lenalidomide is considered a key drug in the treatment of patients with multiple myeloma (MM), an incurable haematological cancer. In fact, most ...

Lenalidomide (oral route) - Mayo Clinic

Lenalidomide is also used in combination with dexamethasone to treat multiple myeloma (plasma cell cancer). It is also used as maintenance ...

Lenalidomide plus Dexamethasone for Relapsed or Refractory ...

The immunomodulatory drug thalidomide has activity in about one third of patients with relapsed or refractory multiple myeloma; response rates ...

REVLIMID® (lenalidomide) - Official Patient Website

REVLIMID is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with the medicine dexamethasone, or as maintenance ...

FDA Approves New Use for Lenalidomide in Multiple Myeloma

Patients with multiple myeloma can receive lenalidomide as maintenance therapy after receiving an autologous stem cell transplant for the disease.

Mechanism of action of lenalidomide in hematological malignancies

It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been ...

Treatment of patients with multiple myeloma progressing on frontline ...

Lenalidomide is increasingly being used as part of frontline therapy in newly diagnosed multiple myeloma. This agent is typically administered until disease ...

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients ...

Lenalidomide (Revlimid, Celgene) is an immunomodulatory drug that, in combination with dexamethasone, is a standard treatment option for ...

Prolonged lenalidomide maintenance therapy improves the depth of ...

Lenalidomide is an immunomodulatory drug approved for maintenance treatment in newly diagnosed multiple myeloma, and it has been shown to ...

Optimizing the use of lenalidomide in relapsed or refractory multiple ...

When given as monotherapy, lenalidomide is moderately active in patients with relapsed or refractory multiple myeloma (RRMM). However, superior efficacy was ...

Clinical perspectives on the optimal use of lenalidomide plus ...

Combinations of lenalidomide, bortezomib, and dexamethasone (RVd) are recommended for the treatment of newly diagnosed multiple myeloma (NDMM).

Lenalidomide (Revlimid®) - Macmillan Cancer Support

Lenalidomide is used to treat myeloma, some types of lymphoma and myelodysplastic syndromes (MDS). Lenalidomide is both a targeted therapy drug and an ...

Lenalidomide (Revlimid) - Cancer Research UK

Lenalidomide is a cancer drug. It is also known by its brand name Revlimid. It is a treatment for:

Multiple myeloma: Initial treatment - UpToDate

Outline · Four-drug regimens · - Daratumumab, bortezomib, lenalidomide, dexamethasone · - Isatuximab-based four-drug regimens · Three-drug ...

Revlimid (Lenalidomide) - Myeloma Research News

Revlimid (lenalidomide) is an immunomodulatory anti-cancer treatment developed by Celgene for multiple myeloma and other diseases.

Lenalidomide - Wikipedia

Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic ...

Lenalidomide in Multiple Myeloma: Review of Resistance ... - MDPI

One of the milestones in the treatment of MM was the implementation of immunomodulatory drugs (IMiDs). Lenalidomide (LEN) is probably the most commonly used ...

Multiple Myeloma Treatment Option | REVLIMID® (lenalidomide)

REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not ...